Metabolic Effects of a Green Tea Extract in Multiple Sclerosis Patients
Not Applicable
Completed
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Dietary Supplement: Capsules with 160 mg Teavigo (at least 94% EGCG)Dietary Supplement: Placebo
- Registration Number
- NCT01417312
- Lead Sponsor
- Charite University, Berlin, Germany
- Brief Summary
This study aims to investigate metabolic effects of a standardized green tea extract, containing a defined amount of epigallocatechin-3-gallate (EGCG), in multiple sclerosis patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- Patients with relapsing-remitting multiple sclerosis
- stable treatment with glatiramer acetate at least 6 months prior to inclusion
- Expanded disability status scale < 4.5
- Normal weight, overweight
Exclusion Criteria
- Primary or secondary progressive forms of multiple sclerosis
- Clinically relevant heart, lung, liver, kidney diseases
- Habitual caffeine intake over 300 mg per day
- Habitual consumption of green tea
- Alcohol or drug abuse
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Green tea extract Capsules with 160 mg Teavigo (at least 94% EGCG) - Placebo Placebo -
- Primary Outcome Measures
Name Time Method Fasting and postprandial lipid oxidation in grams per hour, assessed by indirect calorimetry, after 3 months intake of green tea extract versus placebo Three months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Franz-Volhard Clinical Research Center at the Experimental and Clinical Research Center, Charité University Medicine Berlin and Max Delbrueck Center for Molecular Medicine
🇩🇪Berlin, Germany